BridgeBio Pharma, Inc. presented data from the ATTRibute-CM study, showing Acoramidis led to a 44% reduction in the risk of cardiovascular mortality (CVM) over 42 months for patients with ATTR-CM. Acoramidis also reduced the risk of composite CVM or first cardiovascular hospitalization by 46%, demonstrating high disease stabilization or improvement versus progression. These findings set a new standard for CVM outcomes. Acoramidis is approved as Attruby by the U.S. FDA and BEYONTTRA by European authorities. Future data presentations will further highlight the benefits of Attruby for patients with ATTR-CM.

Read more at GlobeNewswire: Acoramidis Demonstrates Statistically Significant Reduction